CD34 selected progenitors cell
Showing 26 - 50 of >10,000
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,
Recruiting
- Stem Cell Transplant Complications
- +4 more
- Radiation
- +7 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 19, 2023
Sickle Cell-thalassemia Disease, Thalassemia Trial in Washington (peripheral blood stem cell graft that are CD34+ selected)
Active, not recruiting
- Sickle Cell-thalassemia Disease
- Thalassemia
- peripheral blood stem cell graft that are CD34+ selected
-
Washington, District of ColumbiaChildrens National Medical Center
Jul 15, 2021
Study of Mast Cell Precursors
Completed
- Mastocytosis
- Healthy Volunteer
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Nov 4, 2022
Hematologic Malignancies Trial in New York (Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan)
Recruiting
- Hematologic Malignancies
- Busulfan 3.2 mg/kg/day
- +5 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 14, 2022
Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor Trial in Miami (T-cell Receptor a/ß Depleted Donor Lymphocyte
Recruiting
- Lymphoid Leukemia, Acute
- +2 more
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc
May 24, 2022
Sickle Cell Disease Trial in Boston (BEAM-101)
Not yet recruiting
- Sickle Cell Disease
- BEAM-101
-
Boston, MassachusettsBoston Children's Hospital
Jul 11, 2022
Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Oct 11, 2022
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,
Recruiting
- HIV Infection
- +10 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
La Jolla, California
- +3 more
Dec 7, 2022
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection Trial in Los Angeles (Donor CD34+,
Not yet recruiting
- End Stage Kidney Disease
- +3 more
- Donor CD34+, CD3+. and belumosudil
-
Los Angeles, CaliforniaUniversity of California, Los Angeles
Apr 6, 2023
Beta-Thalassemia, Thalassemia, Hematologic Diseases Trial (CTX001)
Not yet recruiting
- Beta-Thalassemia
- +6 more
- CTX001
- (no location specified)
Jul 26, 2022
Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), MDS (MDS) Trial in New York (other, radiation, drug)
Recruiting
- Acute Myeloid Leukemia (AML)
- +2 more
- Personalized rATG (P-rATG)
- +7 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Aug 31, 2022
Sickle Cell Disease Trial in Los Angeles (ßAS3-FB vector transduced peripheral blood CD34+ cells)
Recruiting
- Sickle Cell Disease
- βAS3-FB vector transduced peripheral blood CD34+ cells
-
Los Angeles, CaliforniaUniversity of California, Los Angeles (UCLA)
Apr 9, 2022
Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector
Not yet recruiting
- Lymphoid Leukemia
- Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
- Treg CD34+ HSPC (Orca-T)
-
Palo Alto, CaliforniaStanford Cancer Center
Aug 17, 2022
Anemia, Sickle Cell Trial in Duarte (Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with
Terminated
- Anemia, Sickle Cell
- Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 14, 2021
Wiskott-Aldrich Syndrome Trial in Atlanta, Milan (OTL-103)
Active, not recruiting
- Wiskott-Aldrich Syndrome
- OTL-103
-
Atlanta, Georgia
- +1 more
Sep 27, 2022
Graft Vs Host Disease, Graft-versus-host-disease Trial in San Francisco (CliniMacs®)
Recruiting
- Graft Vs Host Disease
- Graft-versus-host-disease
- CliniMacs®
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 2, 2022
Sickle Cell Disease Trial in United States (bb1111)
Recruiting
- Sickle Cell Disease
- bb1111
-
Birmingham, Alabama
- +8 more
Jul 15, 2022
Plasma Cell Myeloma Trial in Omaha (drug, procedure, biological)
Active, not recruiting
- Plasma Cell Myeloma
- Melphalan
- +4 more
-
Omaha, NebraskaUniversity of Nebraska Medical Center
Nov 21, 2022
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease Trial in Pittsburgh (Cyclophosphamide, Mesna,
Recruiting
- Systemic Sclerosis
- +3 more
- Cyclophosphamide
- +8 more
-
Pittsburgh, Pennsylvania
- +2 more
Dec 17, 2021
Leukemia, Myelodysplastic Syndrome, Lymphoma Trial in New York (CliniMACS Fractionation system (Arm A), CliniMACS Fractionation
Completed
- Leukemia
- +2 more
- CliniMACS Fractionation system (Arm A)
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 12, 2022
Myeloid Chimerism Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (CliniMACS CD34 Reagent)
Recruiting
- Myeloid Chimerism
- CliniMACS CD34 Reagent
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 7, 2022
Metachromatic Leukodystrophy, Adrenoleukodystrophy Trial in Shenzhen (transduced CD34+ hematopoietic stem cell)
Recruiting
- Metachromatic Leukodystrophy
- Adrenoleukodystrophy
- transduced CD34+ hematopoietic stem cell
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital, The First Affiliated Hospital
May 25, 2022
Severe Combined Immunodeficiency, X Linked, Gene Therapy Trial in United Kingdom, United States (autologous CD34+ cell
Recruiting
- Severe Combined Immunodeficiency, X Linked
- Gene Therapy
- autologous CD34+ cell transduced with G2SCID vector
-
Los Angeles, California
- +4 more
Jul 19, 2022